Table 1 Baseline characteristics of the study cohort according to squamous cell carcinoma and adenocarcinoma histology.
SQCC | ADC | p-Value | Other | |
|---|---|---|---|---|
(n = 54) | (n = 56) | (n = 7) | ||
Age, years (median [IQR]) | 63[55.25–69.75] | 62[55.75–68.25] | 0.788a | 68[59–71] |
Smoking status | n = 48 (%) | n = 49 (%) | 0.193b | n = 6 (%) |
Non-smoker | 3(6.2) | 9(18.4) | 2(33.3) | |
Ex-smoker | 27(37.5) | 22(44.9) | 4(66.7) | |
Active smoker | 18(56.2) | 18(36.7) | ||
Macroscopic tumor bed, cm (median [IQR]) | 3.5[2.58–5.42] | 3.5[2.38–4.20] | 0.385a | 4[1.9–4.35] |
Adjusted tumor size, cm (median [IQR]) | 1.24[0.06–2.76] | 1.78[0.05–2.95] | 0.832a | 0[0–3.16] |
ypT-TNM8 | n = 54 (%) | n = 56 (%) | 0.805a | n = 7 (%) |
ypT0 | 6(11.1) | 5(8.9) | 4(57.1) | |
ypT1 | 14(25.9) | 19(33.9) | ||
ypT2a | 11(20.4) | 9(16.1) | ||
ypT2b | 3(5.6) | 3(5.4) | 1(14.3) | |
ypT3 | 6(11.1) | 13(23.2) | 1(14.3) | |
ypT4 | 14(25.9) | 7(12.5) | 1(14.3) | |
TNM8 | n = 54 (%) | n = 56 (%) | 0.557a | n = 7 (%) |
No vital tumor | 3(5.6) | 3(5.4) | 4(57.1) | |
Stage I | 10(18.5) | 12(21.4) | ||
Stage II | 14(25.9) | 11(19.7) | ||
Stage III | 26(48.1) | 26(46.4) | 3(42.9) | |
Stage IV | 1(1.9) | 4(7.1) | ||
Regression | n = 54 (%) | n = 56 (%) | 0.460a | n = 7 (%) |
pCR | 3(5.6) | 4(7.1) | 4(57.1) | |
<1% | 9(16.7) | 9(16.1) | ||
1–10% | 9(16.7) | 6(10.7) | ||
11–49% | 9(16.7) | 6(10.7) | 1(14.3) | |
≥50% | 24(44.3) | 31(55.4) | 2(28.6) | |
PRSC | n = 54 (%) | n = 56 (%) | 0.332a | n = 7 (%) |
Low risk | 23(42.6) | 21(37.5) | 4(57.1) | |
Intermediate risk | 14(25.9) | 25(44.6) | 1(14.3) | |
High risk | 17(31.5) | 10(17.9) | 2(28.6) | |
Neoadjuvant chemotherapy | n = 53 (%) | n = 55 (%) | 0.551b | n = 7 (%) |
Cisplatin + docetaxel | 31(58.5) | 31(56.4) | 6(85.7) | |
Carboplatin + paclitaxel | 3(5.7) | 2(3.6) | ||
Cisplatin + pemetrexed | 6(11.3) | 7(12.7) | ||
Cisplatin + gemcitabin | 6(11.3) | 3(5.5) | ||
Cisplatin + vinorelbin | 2(3.8) | 7(12.7) | 1(14.3) | |
Cisplatin + etoposid | 1(1.8) | |||
Other | 5(9.4) | 4(7.3) | ||
Neoadjuvant radiotherapy | n = 50 (%) | n = 54 (%) | 0.689b | n = 7 (%) |
No | 38(76) | 38(70.4) | 4(57.1) | |
Yes | 12(24) | 16(29.6) | 3(42.9) | |
Surgical procedure | n = 54 (%) | n = 56 (%) | 0.001b | n = 7 (%) |
Lobectomy | 23(42.6) | 42(75) | 4(57.1) | |
Bilobectomy | 4(7.4) | 1(1.8) | ||
Pneumonectomy | 27(50) | 13(23.2) | 3(42.9) | |
R | n = 53 (%) | n = 55 (%) | 0.031b | n = 7 (%) |
R0 | 41(77.4) | 51(92.7) | 7(100) | |
R1 | 12(22.6) | 4(7.3) |